MX2022009962A - Vacunas y usos de la mismas para inducir una respuesta inmunitaria al sars-cov-2. - Google Patents
Vacunas y usos de la mismas para inducir una respuesta inmunitaria al sars-cov-2.Info
- Publication number
- MX2022009962A MX2022009962A MX2022009962A MX2022009962A MX2022009962A MX 2022009962 A MX2022009962 A MX 2022009962A MX 2022009962 A MX2022009962 A MX 2022009962A MX 2022009962 A MX2022009962 A MX 2022009962A MX 2022009962 A MX2022009962 A MX 2022009962A
- Authority
- MX
- Mexico
- Prior art keywords
- cov2
- sars
- vaccines
- induce
- immune response
- Prior art date
Links
- 230000028993 immune response Effects 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
- 230000036039 immunity Effects 0.000 abstract 2
- 238000002255 vaccination Methods 0.000 abstract 2
- 108091005774 SARS-CoV-2 proteins Proteins 0.000 abstract 1
- 206010046865 Vaccinia virus infection Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 230000037452 priming Effects 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
- 208000007089 vaccinia Diseases 0.000 abstract 1
- 239000013603 viral vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/863—Poxviral vectors, e.g. entomopoxvirus
- C12N15/8636—Vaccina virus vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/14011—Filoviridae
- C12N2760/14211—Marburgvirus, e.g. lake Victoria marburgvirus
- C12N2760/14222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
En el presente documento se proporcionan vectores virales de la vaccinia Ankara modificada recombinantes (rMVA) que comprenden insertos de aminoácidos heterólogas que codifican uno o más de proteínas, péptidos y fragmentos de estos de SARS-CoV-2, unidos operativamente a un promotor compatible con sistemas de expresión de poxvirus que, al expresarse, son capaces de inducir inmunidad de protección. Las composiciones pueden utilizarse en una estrategia de primovacunación o en una estrategia de vacunación primaria y revacunación para proporcionar inmunidad contra el SARS-CoV-2 y sus variantes.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062976913P | 2020-02-14 | 2020-02-14 | |
US202062977402P | 2020-02-16 | 2020-02-16 | |
US202062992710P | 2020-03-20 | 2020-03-20 | |
US202063026580P | 2020-05-18 | 2020-05-18 | |
PCT/US2021/018033 WO2021163622A1 (en) | 2020-02-14 | 2021-02-12 | Vaccines and uses thereof to induce an immune response to sars-cov2 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022009962A true MX2022009962A (es) | 2022-11-09 |
Family
ID=77292751
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022009962A MX2022009962A (es) | 2020-02-14 | 2021-02-12 | Vacunas y usos de la mismas para inducir una respuesta inmunitaria al sars-cov-2. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20220396810A1 (es) |
EP (1) | EP4103231A4 (es) |
JP (1) | JP2023513611A (es) |
KR (1) | KR20220154114A (es) |
CN (1) | CN115529817A (es) |
AU (1) | AU2021220991A1 (es) |
BR (1) | BR112022014884A2 (es) |
CA (1) | CA3167052A1 (es) |
IL (1) | IL295482A (es) |
MX (1) | MX2022009962A (es) |
TW (1) | TW202140794A (es) |
WO (1) | WO2021163622A1 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11576966B2 (en) | 2020-02-04 | 2023-02-14 | CureVac SE | Coronavirus vaccine |
US11241493B2 (en) | 2020-02-04 | 2022-02-08 | Curevac Ag | Coronavirus vaccine |
IL298834A (en) * | 2020-06-10 | 2023-02-01 | Bavarian Nordic As | A recombinantly modified ankara virus (MVA) vaccine will be produced against the corona virus disease |
US20230295655A1 (en) * | 2020-07-31 | 2023-09-21 | Tokyo Metropolitan Institute Of Medical Science | Recombinant vaccinia virus |
KR20230164648A (ko) | 2020-12-22 | 2023-12-04 | 큐어백 에스이 | SARS-CoV-2 변이체에 대한 RNA 백신 |
WO2023020939A1 (en) * | 2021-08-17 | 2023-02-23 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
KR20230031756A (ko) * | 2021-08-27 | 2023-03-07 | 한국과학기술원 | 신종 코로나바이러스 감염증 대응 예방 백신 조성물 |
CA3234490A1 (en) * | 2021-10-07 | 2023-04-13 | Precision NanoSystems ULC | Rna vaccine lipid nanoparticles |
WO2023069461A2 (en) * | 2021-10-19 | 2023-04-27 | Vaxxinity, Inc. | Method for the prevention and treatment of coronavirus disease |
WO2023092023A2 (en) * | 2021-11-17 | 2023-05-25 | City Of Hope | Methods of preventing, treating, or reducing the severity of coronavirus disease 2019 (covid-19) |
WO2023200858A1 (en) * | 2022-04-13 | 2023-10-19 | The Trustees Of Columbia University In The City Of New York | Inhibitory peptides against coronaviruses |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9045727B2 (en) * | 2002-05-17 | 2015-06-02 | Emory University | Virus-like particles, methods of preparation, and immunogenic compositions |
US8080642B2 (en) * | 2003-05-16 | 2011-12-20 | Vical Incorporated | Severe acute respiratory syndrome DNA compositions and methods of use |
US7396914B2 (en) * | 2003-08-04 | 2008-07-08 | University Of Massachusetts | SARS nucleic acids, proteins, antibodies, and uses thereof |
EP3312272B1 (en) * | 2004-10-08 | 2019-08-28 | The Government of The United States of America as represented by The Secretary of The Department of Health and Human Services | Modulation of replicative fitness by using less frequently used synonymous codons |
TWI526539B (zh) * | 2010-12-22 | 2016-03-21 | 苜蓿股份有限公司 | 植物中生產類病毒顆粒(vlp)的方法及以該方法生產之vlp |
ES2944314T3 (es) * | 2016-01-08 | 2023-06-20 | Geovax Inc | Composiciones y procedimientos para generar una respuesta inmunitaria frente a un antígeno asociado a un tumor |
EP3402888B1 (en) * | 2016-01-12 | 2020-08-26 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Means and methods for treating hbv |
WO2018170347A1 (en) * | 2017-03-17 | 2018-09-20 | Modernatx, Inc. | Zoonotic disease rna vaccines |
AU2021226592A1 (en) * | 2020-02-26 | 2022-09-22 | The Governors Of The University Of Alberta | Recombinant poxvirus based vaccine against SARS-CoV-2 virus |
US11130787B2 (en) * | 2020-06-11 | 2021-09-28 | MBF Therapeutics, Inc. | Alphaherpesvirus glycoprotein d-encoding nucleic acid constructs and methods |
EP3928789A1 (en) * | 2020-06-24 | 2021-12-29 | Consejo Superior de Investigaciones Científicas (CSIC) | Mva-based vaccine against covid-19 expressing sars-cov-2 antigens |
-
2021
- 2021-02-12 MX MX2022009962A patent/MX2022009962A/es unknown
- 2021-02-12 WO PCT/US2021/018033 patent/WO2021163622A1/en unknown
- 2021-02-12 IL IL295482A patent/IL295482A/en unknown
- 2021-02-12 KR KR1020227031509A patent/KR20220154114A/ko unknown
- 2021-02-12 JP JP2022549163A patent/JP2023513611A/ja active Pending
- 2021-02-12 CN CN202180015836.7A patent/CN115529817A/zh active Pending
- 2021-02-12 BR BR112022014884A patent/BR112022014884A2/pt unknown
- 2021-02-12 CA CA3167052A patent/CA3167052A1/en active Pending
- 2021-02-12 AU AU2021220991A patent/AU2021220991A1/en active Pending
- 2021-02-12 EP EP21754084.8A patent/EP4103231A4/en active Pending
- 2021-02-17 TW TW110105390A patent/TW202140794A/zh unknown
-
2022
- 2022-08-15 US US17/888,131 patent/US20220396810A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN115529817A (zh) | 2022-12-27 |
IL295482A (en) | 2022-10-01 |
AU2021220991A1 (en) | 2022-09-29 |
EP4103231A4 (en) | 2024-03-27 |
KR20220154114A (ko) | 2022-11-21 |
US20220396810A1 (en) | 2022-12-15 |
CA3167052A1 (en) | 2021-08-19 |
TW202140794A (zh) | 2021-11-01 |
EP4103231A1 (en) | 2022-12-21 |
WO2021163622A1 (en) | 2021-08-19 |
BR112022014884A2 (pt) | 2022-10-11 |
JP2023513611A (ja) | 2023-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022009962A (es) | Vacunas y usos de la mismas para inducir una respuesta inmunitaria al sars-cov-2. | |
MY193417A (en) | Recombinant modified vaccinia virus ankara (mva) filovirus vaccine | |
JP2016510989A5 (es) | ||
CO2021004188A2 (es) | Vacuna contra el virus de la peste porcina africana | |
Baur et al. | Immediate-early expression of a recombinant antigen by modified vaccinia virus ankara breaks the immunodominance of strong vector-specific B8R antigen in acute and memory CD8 T-cell responses | |
CA2293692A1 (en) | Methods and reagents for vaccination which generate a cd8 t cell immune response | |
MX2022010588A (es) | Vacuna basada en poxvirus recombinantes contra el virus sars-cov-2. | |
MX2021015465A (es) | Vacuna para fiebre porcina africana. | |
WO2006037038B1 (en) | Optimized vaccines to provide protection against ebola and other viruses | |
ZA201707985B (en) | Recombinant modified vaccinia virus ankara (mva) foot and mouth disease virus (fmdv) vaccine | |
MXPA02006888A (es) | Flavivirus recombinantes y metodos para utilizar los mismos. | |
IL182357A0 (en) | Malaria prime/boost vaccines | |
WO2006073431A3 (en) | Avipox recombinants expressing foot and mouth disease virus genes | |
WO2004037294A3 (en) | New settings for recombinant adenoviral-based vaccines | |
EA202090738A1 (ru) | Способ безопасного индуцирования иммунитета против rsv | |
WO2010105251A3 (en) | Non-integrating retroviral vector vaccines | |
AR124928A2 (es) | Vacuna de herpesvirus-1 equino recombinante que contiene glicoproteína c mutada y usos de la misma | |
PH12021550030A1 (en) | Nucleotide sequences encoding peptide antigens of sars-cov-2 virus and use thereof | |
WO2019006401A3 (en) | LISTERIA-BASED IMMUNOGENIC COMPOSITIONS COMPRISING HETERICCLIENT WILMS TUMOR PROTEIN ANTIGENS AND METHODS OF USE THEREOF | |
WO2017161360A4 (en) | Multimodal vector for dendritic cell infection | |
EP2552490A4 (en) | INFLUENZA MATRIX 2 PROTEIN ECKTOMOMAS, EXPRESSION SYSTEM THEREFOR AND USES THEREOF | |
WO2014205579A4 (en) | Modified matrix proteins of vesicular stomatitis virus | |
MX2023000041A (es) | Composiciones y metodos para inducir una respuesta inmunitaria contra coronavirus. | |
NZ598605A (en) | Vaccine against african horse sickness virus | |
MX2017014417A (es) | Vacunas contra el dengue. |